1Gaytant MA, Steegers EA, Semmekrot BA, et al.Congenital cytomegalovirus infection: review of theepidemiology and outcome [J]. Obstet Gynecol Surv,2002,57(4) :245 - 256.
2Bankier AT, Beck S, Bohni R, et al. The DNA sequence of the human cytomegalovirus genome [ J ].DNA Seq, 1991,2(1):1 - 12.
3Hensel G, Meyer H, Gartner S, et al. Nuclear location of human cytomegalovirus tegument protein pp150(ppUL32) [J]. J Gen Virol,1995,76:1591-1601.
4Dal MP, Bessia C, Ripalti A, et al. Stabley expressed antisense RNA to cytomegalovirus UL 83 inhibits viral replication [J]. J Virol, 1996,70 (4) : 2086 - 2094.
5Schmolke S, Kern H, Drescher P, et al. The dominant phosphoprotein pp65 (UL 83) of huamn cytomegalovi-rus is dispensable for growth in cell culture[J]. J GenVirol, 1995,69 (10) : 5959 - 5968.
6Vaz SJ, Lule J, Rohrlich P, et al. Ex vivo stimulation and expansion of both CD4 ( + ) and CD8 ( + ) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65 [J]. J Virol, 2001,75(17) : 7840 - 7847.
7Wills MR, Carmichael A, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structureal protein pp65:frequency, specificity, and T-cell receptor usage of pp65-specific CTL [J ]. J Virol, 1996, 70 ( 11 ) : 7569 -7579.
8Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IEl-specificCTLs[J]. J Infect Dis, 2000,181(5) : 1537 - 1546.
9Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A 0201 restricted peptide-based vaccine against human cytomegalovirus infection [ J ], Blood,1997,90:1751 - 1767.
10Beninga J, Kropff B, Mach M, et al. Comparative analysis of fourteen individual HCMV proteins forhelper T cell response[ J ]. J Gen Virol, 1995,76 (pt. 1 ) :153 - 160.
